Medical Tidbits,US Hospital Pioneers Use of First Mobile Compounding Cleanroom

Duke Raleigh Hospital Pioneers Use of Certified Mobile Sterile Compounding Unit (PRNewsFoto/Germfree Labs)

Duke Raleigh Hospital Pioneers Use of Certified Mobile Sterile Compounding Unit

RALEIGH, N.C., Sept. 24, 2015 /PRNewswire/ — Duke Raleigh Hospital recently became the first healthcare facility to utilize a certified USP 797 mobile cleanroom to assure uninterrupted pharmacy services. The advanced pharmacy unit, created by Germfree Labs, allowed the hospital to maintain separate, on-site sterile drug compounding operations during a major renovation more

MetaStat Announces Positive Topline Results of a MetaSite Breast™ Prognostic Study in Invasive Breast Cancer

BOSTON–(BUSINESS WIRE)–MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today announced positive preliminary results from a study of MetaSite Breast™ in patients with ER-positive, HER2-negative early stage invasive breast cancer. The prognostic study met its prospectively defined primary endpoint. It demonstrated the MetaSite Breast™ Score is significantly and directly associated with increased risk of distant metastasis in ER-positive, HER2-negative invasive breast cancer for both high (>35 MetaSites) versus low (<12 MetaSites) MetaSite scores (OR = 3.4; 95%CI = 2.8-4.1; P=0.0002) as well as between intermediate (12-35 MetaSites) and low MetaSite scores (OR=3.24; 95%CI = 2.6-3.9; P=0.0006). read more

FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome  

BOSTON, Sept. 24, 2015 /PRNewswire/ — Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development* to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company’s novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS). read more

Novartis launches ‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries

New York, September 24, 2015 – Novartis today announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for USD 1 per treatment, per month. read more

SCIEX Announces Exclusive Reseller Agreement with Advaita Bioinformatics

FRAMINGHAM, Mass.–(EON: Enhanced Online News)–SCIEX, a global leader in life science analytical technologies, today announced an exclusive reseller agreement with Advaita Bioinformatics, a leader in the development of bioinformatic solutions for multi-omic biological data, that will allow SCIEX to sell Advaita licenses of iPathwayGuide, as part of the OneOmics™ project. Under the agreement, Advaita’s web-based application for Pathway Impact Analysis, provides SCIEX’s customers with access to iPathwayGuide, to interpret SWATH® Acquisition based next-generation proteomics (NGP) data, at a systems biology level, and integrates with other ‘omics’ data in a cloud computing environment. read more

Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa

IRVINE , Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on September 23, dosing commenced of the first patients enrolled in Rocket 4, the Company’s fourth Phase 3 clinical trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) read more



Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.